var data={"title":"Linezolid: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Linezolid: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6467?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">see &quot;Linezolid: Drug information&quot;</a> and <a href=\"topic.htm?path=linezolid-patient-drug-information\" class=\"drug drug_patient\">see &quot;Linezolid: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188966\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zyvox</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188967\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Linezolid;</li>\n      <li>Linezolid Injection;</li>\n      <li>Sandoz-Linezolid;</li>\n      <li>Zyvoxam</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048288\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antibiotic, Oxazolidinone</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443849\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Linezolid is not a preferred agent in treatment of infections requiring prolonged therapy (ie, &gt;2 weeks) due to the risk of serious hematologic and neurologic toxicity. Use of linezolid is generally reserved for treatment of infections due to drug-resistant organisms (eg, MRSA, VRE).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>General dosing, susceptible infection</b> (<i>Red Book</i> 2012): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &lt;1 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;14 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 15 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight 1 to 2 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &le;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA 8 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Body weight &gt;2 kg: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bacteremia:</b> Oral, IV: <b>Note:</b> Treatment should continue for 10 to 28 days depending on the organism</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &lt;34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &lt;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &ge;7 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;34 weeks and PNA 0 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Pneumonia, community- or hospital-acquired:</b> Oral, IV: <b>Note:</b> Treatment should continue for 10 to 14 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &lt;34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &lt;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &ge;7 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;34 weeks and PNA 0 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Skin and skin structure infections, complicated and uncomplicated:</b> Oral, IV: <b>Note:</b> Treatment should continue for 10 to 14 days; reserve IV use for complicated infections only.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &lt;34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &lt;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &ge;7 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;34 weeks and PNA 0 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Vancomycin-resistant <i>Enterococcus faecium</i> (VREF) infection:</b> Oral, IV: <b>Note:</b> Treatment should continue for 14 to 28 days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &lt;34 weeks:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &lt;7 days: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">PNA &ge;7 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GA &ge;34 weeks and PNA 0 to 28 days: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Case reports describe the use of higher doses up to 12 to 15 mg/kg/dose every 8 hours to treat VRE endocarditis and meningitis/ventriculitis in former premature neonates (n=2; GA: 26, 35 weeks; age at treatment: Term) (Ang 2003; Kumar 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048281\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">see &quot;Linezolid: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;margin-right:4em;display:inline\">\n      <b>Note:</b> Linezolid is not a preferred agent in treatment of infections requiring prolonged therapy (ie, &gt;2 weeks) due to the risk of serious hematologic and neurologic toxicity. Use of linezolid is generally reserved for treatment of infections due to drug-resistant organisms (eg, MRSA, VRE).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infection (mild, moderate, or severe)</b> (<i>Red Book</i> 2012): Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours, maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bacteremia:</b> Oral, IV: <b>Note:</b> Treatment should continue for 10 to 28 days depending on the organism.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bone and joint infection</b> (Liu 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Osteomyelitis [<i>S. aureus</i> (methicillin-resistant)]: Oral, IV: <b>Note:</b> Treatment should continue for a minimum of 4 to 6 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Septic arthritis [<i>S. aureus</i> (methicillin-resistant)]: Oral, IV: <b>Note:</b>Treatment should continue for a minimum of 3 to 4 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter (peritoneal dialysis); exit-site or tunnel infection</b> (Warady [ISPD 2012]): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;5 years: 10 mg/kg/dose three times daily; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;5 years to 11 years: 10 mg/kg/dose twice daily; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Catheter-related infections, Staphylococcal (methicillin-resistant) or enterococcal (resistant) (confirmed infection):</b> Oral, IV: <b>Note:</b> Not recommended use for empiric treatment (Mermel 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS infection: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brain abscess, subdural empyema, spinal epidural abscess [<i>S. aureus</i> (methicillin-resistant)]: Oral, IV: <b>Note:</b> Treatment should continue for 4 to 6 weeks (Liu 2011). <b>Note:</b> The manufacturer does not recommend the use of linezolid for empiric treatment of pediatric CNS infections since therapeutic linezolid concentrations are not consistently achieved or maintained in the CSF of patients with ventriculoperitoneal shunts.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningitis [<i>S. aureus</i> (methicillin-resistant)]: Oral, IV: <b>Note:</b> Treatment should continue for 2 weeks (Liu 2011; Tunkel 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Endocarditis, treatment [<i>E. faecium</i> (vancomycin-resistant)]:</b> Oral, IV: <b>Note:</b> Treatment should continue for at least 8 weeks (Baddour 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Peritonitis (peritoneal dialysis)</b> (Warady [ISPD 2012]): Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;5 years: 10 mg/kg/dose three times daily; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 5 to 11 years: 10 mg/kg/dose twice daily; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg/dose twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Pneumonia</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Community- or hospital-acquired (non-MRSA): Oral, IV: <b>Note:</b> Treatment should continue for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>S. aureus</i> (methicillin-resistant): Oral, IV: <b>Note:</b> Treatment should continue for 7 to 21 days depending on severity (Liu 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Septic thrombosis of cavernous or dural venous sinus [<i>S. aureus</i> (methicillin-resistant)]:</b> Oral, IV: <b>Note:</b> Treatment should continue for 4 to 6 weeks (Liu 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Skin and skin structure infections: Note:</b> Treatment should continue for 10 to 14 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Uncomplicated:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;5 years: Oral: 10 mg/kg/dose every 8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 5 to 11 years: Oral: 10 mg/kg/dose every 12 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Complicated:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children &lt;12 years: Oral, IV: 10 mg/kg/dose every 8 hours; maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: Oral, IV: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Tuberculosis, multidrug-resistant:</b> Limited data available: Oral: <b>Note:</b> Experience in pediatric patients reflects extrapolation of dosing approach used in adult patients which includes a lower daily dose to decrease risk of adverse effects due to the anticipated long duration of therapy and if toxicity does occur, further dosage reductions (a 25% to 50% dose decrease or increased dosing interval have been used); reported treatment duration dependent upon clinical course; reported range: 13 to 36 months in pediatric patients. All reports describe linezolid as part of a multidrug antimycobacterial regimen; other reported agents within the combination therapy were variable, dependent upon specific organism sensitivities, and generally included 3 to 5 other agents.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months and Children: 10 to 12 mg/kg/dose twice daily; maximum dose: 600 mg; dosing based on case reports describing successful treatment in infants and a young child (n=3; ages: 4.5 months, 11 months, and 23 months) (Pinon 2010; Schaaf 2009). Use has also been reported in a 10-year old child, treatment was successfully completed with dosing of 600 mg once daily (Condos 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: 600 mg once daily was reported in a retrospective review of 30 patients (n= four adolescents) and a case report (patient age: 14 years) (Dauby 2011; Schecter 2010). In another case series, 600 mg twice daily dosing was used for the initial 2 weeks of therapy and then decreased to once daily dosing; at reduced dosage, patients seemed to have decreased hematologic toxicity while neurotoxicity remained unchanged (Park 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Vancomycin-resistant <i>Enterococcus faecium</i> (VREF) infections:</b> Oral, IV: <b>Note:</b> Treatment should continue for 14 to 28 days.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children &lt;12 years: 10 mg/kg/dose every 8 hours, maximum dose: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Oral, IV: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Usual dosage:</b> Oral, IV: 600 mg every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Indication-specific dosing:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>MRSA infections</b> (Liu 2011): Oral, IV: 600 mg every 12 hours; duration of therapy dependent upon site of infection and clinical response</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Pneumonia, community- or hospital-acquired:</b> Oral, IV: 600 mg every 12 hours for 10 to 14 days. <b>Note:</b> In contrast to the manufacturer&rsquo;s recommendations, current guidelines for the treatment of community-acquired, healthcare-, hospital-, and ventilator-associated pneumonia recommend that the duration of therapy be reduced to as short as 7 days (vs 10-14 days) in patients who demonstrate good clinical response (ATS/IDSA 2005; ATS/IDSA 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Skin and skin structure infections</b></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Complicated: Oral, IV: 600 mg every 12 hours for 10 to 14 days. <b>Note:</b> For diabetic foot infections, initial treatment duration is up to 4 weeks depending on severity of infection and response to therapy (Lipsky 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Uncomplicated: Oral: 400 mg every 12 hours for 10 to 14 days. <b>Note:</b> 400 mg dose is recommended in the product labeling; however, 600 mg dose is commonly employed clinically; consider 5- to 10-day treatment course as opposed to the manufacturer recommended 10 to 14 days (Liu 2011; Stevens 2005). For diabetic foot infections, may extend treatment duration up to 4 weeks if slow to resolve (Lipsky 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>VREF infections, including concurrent bacteremia:</b> Oral, IV: 600 mg every 12 hours for 14 to 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in renal impairment:</b> No adjustment is recommended. The two primary metabolites may accumulate in patients with renal impairment but the clinical significance is unknown. Weigh the risk of accumulation of metabolites versus the benefit of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: The following adjustments have been recommended (Aronoff 2007): <b>Note:</b> Renally adjusted dose recommendations are based on doses of 10 mg/kg/dose every 8 hours (for ages &lt;5 years) or every 12 hours (for ages 5 to 11 years).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent hemodialysis: 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis (PD): 10 mg/kg/dose every 12 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Intermittent hemodialysis (administer after hemodialysis on dialysis days): Dialyzable (~30% removed during 3-hour dialysis session): If administration time is not immediately after dialysis session, may consider administration of a supplemental dose especially early in the treatment course to maintain levels above the MIC (Brier 2003). Others have recommended no supplemental dose or dosage adjustment for patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD) (Heintz 2009; Trotman 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment in hepatic impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment (Child Pugh class A or B): No adjustment is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe hepatic impairment (Child Pugh Class C): Use has not been adequately evaluated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188942\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyvox: 200 mg/100 mL (100 mL); 600 mg/300 mL (300 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg/300 mL (300 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyvox: 100 mg/5 mL (150 mL) [orange flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 100 mg/5 mL (150 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zyvox: 600 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188927\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048291\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer with or without food. With reconstituted suspension, gently invert bottle 3-5 times before use. Do not shake. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Parenteral: IV: Check infusion bag for minute leaks and solution for particulate matter prior to administration. Administer without further dilution over 30 to 120 minutes. Do not mix or infuse with other medications. When the same intravenous line is used for sequential infusion of other medications, flush line with D<sub>5</sub>W, NS, or LR before and after infusing linezolid. The yellow color of the injection may intensify over time without affecting potency. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188961\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infusion: Store at 25&deg;C (77&deg;F). Protect from light and freezing. Keep infusion bags in overwrap until ready for use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral suspension: Store at 25&deg;C (77&deg;F); following reconstitution store at room temperature and use suspension within 21 days. Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet: Store at 25&deg;C (77&deg;F). Protect from light and moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048290\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of community-acquired pneumonia, hospital-acquired pneumonia, uncomplicated and complicated skin and soft tissue infections (including diabetic foot infections without concomitant osteomyelitis), and bacteremia caused by susceptible organisms, such as vancomycin-resistant <i>Enterococcus faecium</i> (VREF), <i>Streptococcus pneumoniae</i> including multidrug resistant strains, <i>Staphylococcus aureus</i> including MRSA, <i>Streptococcus pyogenes</i>, or <i>Streptococcus agalactiae</i> (FDA approved in all ages). Has also been used for the treatment of exit-site or tunnel infections in patients with peritoneal dialysis catheters and for the treatment of peritonitis in patients with peritoneal catheters. <b>Note:</b> There have been reports of vancomycin-resistant <i>E. faecium</i> and <i>S. aureus</i> (methicillin-resistant) developing resistance to linezolid during its clinical use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F189002\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zyvox may be confused with Zosyn, Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188999\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness (adults), headache (more common in children, adolescents, and adults), vertigo (children and adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritus (neonates, infants, children, and adolescents; nonapplication site), skin rash (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Increased amylase, increased lactate dehydrogenase (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dysgeusia (adults), increased serum lipase (more common in adults), loose stools (neonates, infants, children, and adolescents), nausea, oral candidiasis (adults), tongue discoloration, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Vulvovaginal candidiasis (adults)</p>\n    <p style=\"text-indent:-4em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (more common in neonates, infants, and children), decreased neutrophils (more common in neonates, infants, and children), decreased platelet count (adults), decreased white blood cells (more common in neonates, infants, and children: 12%), eosinophilia (neonates, infants, children, and adolescents), thrombocytopenia (neonates, infants, and children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests (adults), increased serum alkaline phosphatase (adults), increased serum ALT, increased serum AST (adults), increased serum bilirubin (more common in neonates, infants, and children)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Fungal infection (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen (adults), increased serum creatinine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, angioedema, blurred vision, bone marrow depression, bullous skin disease, <i>Clostridium difficile </i>associated diarrhea, dental discoloration, hypoglycemia, lactic acidosis, optic neuropathy, pancytopenia, peripheral neuropathy, seizure, serotonin syndrome (with concurrent use of other serotonergic agents), severe dermatological reaction, sideroblastic anemia, Stevens-Johnson syndrome, toxic epidermal necrolysis, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188947\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to linezolid or any component of the formulation; concurrent use or within 2 weeks of MAO inhibitors</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Unless monitored for potential increases in blood pressure, linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following: sympathomimetic agents (eg, pseudoephedrine, phenylpropanolamine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine). Unless carefully observed for signs and/or symptoms of serotonin syndrome, linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any of the following: SSRIs, TCAs, serotonin 5-HT<sub>1</sub> receptor agonists (triptans), meperidine or buspirone.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188931\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lactic acidosis: Has been reported with use. Patients who develop recurrent nausea and vomiting, unexplained acidosis, or low bicarbonate levels need immediate evaluation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myelosuppression: Has been reported and may be dependent on duration of therapy (generally &gt;2 weeks of treatment); use with caution in patients with preexisting myelosuppression, in patients receiving other drugs which may cause bone marrow suppression, or in chronic infection (previous or concurrent antibiotic therapy). Weekly CBC monitoring is recommended; consider discontinuation in patients developing myelosuppression (or in whom myelosuppression worsens during treatment). Thrombocytopenia is the most frequently observed blood dyscrasia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral and optic neuropathy (with vision loss): Has been reported in adults and children and may occur primarily with extended courses of therapy &gt;28 days; any symptoms of visual change or impairment warrant immediate ophthalmic evaluation and possible discontinuation of therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs, agents which reduce linezolid's metabolism, or in patients with carcinoid syndrome. Avoid use in such patients unless clinically appropriate and under close monitoring for signs/symptoms of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Carcinoid syndrome: Use with caution and closely monitor for serotonin syndrome in patients with carcinoid syndrome; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes mellitus: Hypoglycemic episodes have been reported; use with caution and closely monitor glucose in diabetic patients. Dose reductions/discontinuation of concurrent hypoglycemic agents or discontinuation of linezolid may be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypertension: Use with caution and closely monitor blood pressure in patients with uncontrolled hypertension; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Use with caution and closely monitor blood pressure in patients with untreated hyperthyroidism; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma: Use with caution and closely monitor blood pressure in patients with pheochromocytoma; linezolid has not been studied in patients with this condition. Do not use in the absence of close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Seizure disorder: Seizures have been reported; use with caution in patients with a history of seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions:  Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: The manufacturer does not recommend the use of linezolid for empiric treatment of pediatric CNS infections since therapeutic linezolid concentrations are not consistently achieved or maintained in the CSF of patients with ventriculoperitoneal shunts. However, limited data in the form of case reports in pediatric and adult patients suggest that linezolid may be useful in treating gram-positive CNS infections that have failed to respond to other treatment options describing successful treatment of documented VRE and <i>Staphylococcus aureus</i> CNS and shunt infections in the literature (Cook 2005; da Silva 2007; Milstone 2007; Shaikh 2001; Villani 2002). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Phenylalanine: Some products may contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Unnecessary use may lead to the development of resistance to linezolid; consider alternatives before initiating outpatient treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Catheter-related bloodstream infections (CRBSI): Linezolid should not be used in the empiric treatment of CRBSI, but may be appropriate for targeted therapy (Mermel 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299606\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> Monoamine Oxidase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188936\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12555&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Monoamine Oxidase Inhibitors may increase the serum concentration of Apraclonidine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: Monoamine Oxidase Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atropine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Atropine (Ophthalmic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: The use of benzhydrocodone is not recommended for patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betahistine: Monoamine Oxidase Inhibitors may increase the serum concentration of Betahistine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Bezafibrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Monoamine Oxidase Inhibitors may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Ophthalmic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Ophthalmic). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Brimonidine (Topical). Monoamine Oxidase Inhibitors may increase the serum concentration of Brimonidine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of BuPROPion. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, blood pressure elevations been reported.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cerebrolysin: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Codeine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Codeine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclobenzaprine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproheptadine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Cyproheptadine. Cyproheptadine may diminish the serotonergic effect of Monoamine Oxidase Inhibitors. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deutetrabenazine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Deutetrabenazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Dexmethylphenidate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dextromethorphan: Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diethylpropion: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Diethylpropion. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dihydrocodeine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diphenoxylate: May enhance the hypertensive effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Domperidone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Domperidone. Monoamine Oxidase Inhibitors may diminish the therapeutic effect of Domperidone. Domperidone may diminish the therapeutic effect of Monoamine Oxidase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOPamine: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of DOPamine.  Management: Initiate dopamine at no greater than one-tenth (1/10) of the usual dose in patients who are taking (or have taken within the last 2 to 3 weeks) monoamine oxidase inhibitors. Monitor for an exaggerated hypertensive response to dopamine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droxidopa: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Droxidopa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPINEPHrine (Oral Inhalation): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of EPINEPHrine (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Epinephrine (Racemic): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Epinephrine (Racemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heroin: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Heroin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROcodone.  Management: Consider alternatives to this combination when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROmorphone: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of HYDROmorphone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indoramin: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Indoramin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isometheptene: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Isometheptene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI. Management: The concomitant use of nonselective monoamine oxidase inhibitors (MAOIs) and levodopa is contraindicated. Discontinue the nonselective MAOI at least two weeks prior to initiating levodopa. Monitor patients taking a selective MAOIs and levodopa.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levonordefrin: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Levonordefrin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Lithium.  Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maprotiline: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meperidine: Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Meptazinol: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Meptazinol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mequitazine: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Mequitazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methyldopa: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Methyldopa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Monoamine Oxidase Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Methylphenidate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: Monoamine Oxidase Inhibitors may enhance the neurotoxic effect of Mianserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: Linezolid may enhance the serotonergic effect of Mirtazapine. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Moclobemide: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Moclobemide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Linezolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Liposomal): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Morphine (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefazodone: Linezolid may enhance the serotonergic effect of Nefazodone. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nefopam: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Nefopam. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome. Management: Seek alternatives when possible. Avoid use of oxycodone/naltrexone during and within 14 days after monoamine oxidase inhibitor treatment. Non-US labeling for some oxycodone products states that such use is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyMORphone: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pheniramine: May enhance the anticholinergic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: May enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pindolol: Monoamine Oxidase Inhibitors may enhance the hypotensive effect of Pindolol.  Management: Canadian labeling for pindolol states that concurrent use with a monoamine oxidase inhibitor is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pizotifen: Monoamine Oxidase Inhibitors may enhance the anticholinergic effect of Pizotifen. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reboxetine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: Linezolid may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin 5-HT1D Receptor Agonists: Monoamine Oxidase Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.<b> Exceptions: </b>Eletriptan; Frovatriptan; Naratriptan.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Linezolid may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.  Management: Due to a risk of serotonin syndrome/serotonin toxicity, discontinue serotonin modulators 2 weeks prior to the administration of linezolid. If urgent initiation of linezolid is needed, discontinue serotonin modulators immediately and monitor closely.<b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin/Norepinephrine Reuptake Inhibitors: Linezolid may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. Management: Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: Linezolid may enhance the hypertensive effect of Sympathomimetics.  Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the additive effects of norepinephrine may lead to adverse cardiovascular effects. Tapentadol may enhance the serotonergic effect of Monoamine Oxidase Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrabenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrozoline (Nasal): Monoamine Oxidase Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tianeptine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraZODone: Linezolid may enhance the serotonergic effect of TraZODone. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Linezolid may enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tryptophan: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188963\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine. Avoid beverages containing tyramine. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188938\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188950\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in some animal reproduction studies at doses that were also maternally toxic. Information related to linezolid use during pregnancy is limited. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048287\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC (weekly), particularly in patients at increased risk for bleeding, patients with pre-existing thrombocytopenia or myelosuppression, patients with chronic infection who have received or who are on concomitant antibiotics, or concomitant medications that decrease platelet count or function or produce bone marrow suppression, and inpatients requiring &gt;2 weeks of therapy; number and type of stools/day for diarrhea; visual function in patients requiring &ge;3 months of therapy or in patients reporting new visual symptoms </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188930\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial protein synthesis by binding to bacterial 23S ribosomal RNA of the 50S subunit. This prevents the formation of a functional 70S initiation complex that is essential for the bacterial translation process. Linezolid is bacteriostatic against enterococci and staphylococci and bactericidal against most strains of streptococci.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188946\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and extensive</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm neonates &lt;1 week: 0.81 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Full-term neonates &lt;1 week: 0.78 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Full-term neonates &ge;1 week to &le;28 days: 0.66 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &gt;28 days to &lt;3 months: 0.79 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 3 months to 11 years: 0.69 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 0.61 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 0.65 L/kg </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Adults: 31% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via oxidation of the morpholine ring, resulting in two inactive metabolites (aminoethoxyacetic acid, hydroxyethyl glycine); minimally metabolized, may be mediated by cytochrome P450</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: ~100% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm neonates &lt;1 week: 5.6 hours</p>\n    <p style=\"text-indent:-4em;margin-left:6em;text-align:justify;\">Full-term neonates &lt;1 week: 3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Full-term neonates &ge;1 week to &le;28 days: 1.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants &gt;28 days to &lt;3 months: 1.8 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 3 months to 11 years: 2.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adolescents: 4.1 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 4.9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Adults: Oral: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~30% of total dose as parent drug, ~50% of total dose as metabolites); two metabolites of linezolid may accumulate in patients with severe renal impairment; feces (~9% of total dose as metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nonrenal clearance: Adults: ~65%</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Preterm neonates &lt;1 week: 2 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Full-term neonates &lt;1 week: 3.8 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Full-term neonates &ge;1 week to &le;28 days: 5.1 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants &gt;28 days to &lt;3 months: 5.4 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Infants and Children 3 months to 11 years: 3.8 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adolescents: 2.1 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Adults: 1.7 mL/minute/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188949\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Linezolid in Sodium Chloride Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600MG/300ML 0.9% (300 mL): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Linezolid Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600MG/300ML (300 mL): $75.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zyvox Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/100 mL (100 mL): $72.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600MG/300ML (300 mL): $96.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Linezolid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (150 mL): $820.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Zyvox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/5 mL (150 mL): $1,602.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Linezolid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (20): $3,673.41</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zyvox Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (20): $4,081.61</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F188952\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anozilad (HU);</li>\n      <li>Arlin (BD);</li>\n      <li>Axazolid (LK);</li>\n      <li>Ezolid (BD);</li>\n      <li>Linespan (LB);</li>\n      <li>Linezid (UA);</li>\n      <li>Linox (IN);</li>\n      <li>Litrecan (AR);</li>\n      <li>Lizolid (LK, VN);</li>\n      <li>Macdin (VN);</li>\n      <li>Nel (BD);</li>\n      <li>Nezkil (PK);</li>\n      <li>Nezox (BD);</li>\n      <li>Ziplemol (HU);</li>\n      <li>Zyvix (BD);</li>\n      <li>Zyvoks (UA);</li>\n      <li>Zyvox (AE, AR, AU, BB, BH, BR, CL, CN, CY, EG, GB, HK, ID, IE, IQ, IR, JO, KR, KW, LB, LK, LY, MT, MY, NZ, OM, PE, PH, QA, RU, SA, SG, SY, TH, TW, UY, VE, VN, YE);</li>\n      <li>Zyvoxam (MX);</li>\n      <li>Zyvoxid (AT, BE, BG, CH, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, IL, IS, IT, LT, LU, LV, NL, NO, PL, RO, SE, SI, SK, TR, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. <i>Red Book: 2012 Report of the Committee on Infectious Diseases</i>. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society and Infectious Diseases Society of America, &quot;Guidelines for the Management of Adults With Hospital-Acquired, Ventilator-Associated, and Healthcare-Associated Pneumonia,&quot; <i>Am J Respir Crit Care Med</i>, 2005, 171(4):388-416.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ang JY, Lua JL, Turner DR, et al, &quot;Vancomycin-Resistant <i>Enterococcus faecium</i> Endocarditis in a Premature Infant Successfully Treated With Linezolid,&quot; <i>Pediatr Infect Dis J</i>, 2003, 22(12):1101-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/14688576/pubmed\" target=\"_blank\" id=\"14688576\">14688576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, 167.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al, &quot;Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,&quot; <i>Circulation</i>, 2005, 111(23):e394-434.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15956145/pubmed\" target=\"_blank\" id=\"15956145\">15956145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bradley JS, Byington CL, Shah SS, et al, &ldquo;The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America&rdquo;, <i>Clin Infect Dis</i>, 2011, 53(7):617-30. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/21880587/pubmed\" target=\"_blank\" id=\"21880587\">21880587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brier ME, Stalker DJ, Aronoff GR, et al, &quot;Pharmacokinetics of Linezolid in Subjects With Renal Dysfunction,&quot; <i>Antimicrob Agents Chemother</i>, 2003, 47(9):2775-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/12936973/pubmed\" target=\"_blank\" id=\"12936973\">12936973</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clemett D and Markham A, &ldquo;Linezolid,&rdquo; <i>Drugs</i>, 2000, 59(4):815-27. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/10804037/pubmed\" target=\"_blank\" id=\"10804037\">10804037</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Condos R, Hadgiangelis N, Leibert E, et al, &quot;Case Series Report of a Linezolid-Containing Regimen for Extensively Drug-Resistant Tuberculosis,&quot; <i>Chest</i>, 2008, 134(1):187-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/18628223/pubmed\" target=\"_blank\" id=\"18628223\">18628223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cook AM, Ramsey CN, Martin CA, et al, &ldquo;Linezolid for the Treatment of a Heteroresistant <i>Staphylococcus aureus</i> Shunt Infection,&rdquo; <i>Pediatr Neurosurg</i>, 2005, 41(2):102-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15942282/pubmed\" target=\"_blank\" id=\"15942282\">15942282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    da Silva PS, Monteiro Neto H, and Sejas LM, &ldquo;Successful Treatment of Vancomycin-Resistant Enterococcus Ventriculitis in a Child,&rdquo; <i>Braz J Infect Dis</i>, 2007, 11(2):297-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/17625782/pubmed\" target=\"_blank\" id=\"17625782\">17625782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dauby N, Muylle I, Mouchet F, et al, &quot;Meropenem/Clavulanate and Linezolid Treatment for Extensively Drug-Resistant Tuberculosis,&quot; <i>Pediatr Infect Dis J</i>, 2011, 30(9):812-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/21378593/pubmed\" target=\"_blank\" id=\"21378593\">21378593</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dotis J, Iosifidis E, Ioannidou M, et al, &quot;Use of Linezolid in Pediatrics: A Critical Review,&quot; <i>Int J Infect Dis</i>, 2010, 14(8):e638-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/20106697/pubmed\" target=\"_blank\" id=\"20106697\">20106697</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heintz BH, Matzke GR, Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo; <i>Pharmacotherapy</i>, 2009, 29(5):562-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/19397464/pubmed\" target=\"_blank\" id=\"19397464\">19397464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jungbluth GL, Welshman IR, and Hopkins NK, &quot;Linezolid Pharmacokinetics in Pediatric Patients: An Overview,&quot; <i>Pediatr Infect Dis J</i>, 2003, 22(9 Suppl):153-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/14520140/pubmed\" target=\"_blank\" id=\"14520140\">14520140</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Abdel-Rahman SM, Blumer JL, et al, &ldquo;Single Dose Pharmacokinetics of Linezolid in Infants and Children,&rdquo; <i>Pediatr Infect Dis J</i>, 2000, 19(12):1178-84. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/11144380/pubmed\" target=\"_blank\" id=\"11144380\">11144380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al, &ldquo;Impact of Ontogeny on Linezolid Disposition in Neonates and Infants,&rdquo; <i>Clin Pharmacol Ther</i>, 2003, 74(5):413-22. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/14586382/pubmed\" target=\"_blank\" id=\"14586382\">14586382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar S, Kohlhoff S, Valencia G, et al, &quot;Treatment of Vancomycin-Resistant <i>Enterococcus faecium</i> Ventriculitis in a Neonate,&quot; <i>Int J Antimicrob Agents</i>, 2007, 29(6):740-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/17395431/pubmed\" target=\"_blank\" id=\"17395431\">17395431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lipsky BA, Berendt AR, Deery HG, et al, &quot;Diagnosis and Treatment of Diabetic Foot Infections,&quot; <i>Clin Infect Dis</i>, 2004, 39(7):885-910.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15472838/pubmed\" target=\"_blank\" id=\"15472838\">15472838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al, &quot;Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections in Adults and Children: Executive Summary,&quot; <i>Clin Infect Dis</i>, 2011, 52(3):285-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mermel LA, Allon M, Bouza E, et al, &quot;Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 49(1):1-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/19489710/pubmed\" target=\"_blank\" id=\"19489710\">19489710</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyer B, Kornek GV, Nikfardjam M, et al, &quot;Multiple-Dose Pharmacokinetics of Linezolid During Continuous Venovenous Haemofiltration,&quot; <i>J Antimicrob Chemother</i>, 2005, 56(1):172-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15905303/pubmed\" target=\"_blank\" id=\"15905303\">15905303</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milstone AM, Dick J, Carcon B, et al, &ldquo;Cerebrospinal Fluid Penetration and Bacteriostatic Activity of Linezolid Against <i>Enterococcus faecalis</i> in a Child With a Ventriculoperitoneal Shunt Infection,&rdquo; <i>Pediatr Neurosurg</i>, 2007, 43(5):406-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/17786008/pubmed\" target=\"_blank\" id=\"17786008\">17786008</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park IN, Hong SB, Oh YM, et al, &quot;Efficacy and Tolerability of Daily-Half Dose Linezolid in Patients With Intractable Multidrug-Resistant Tuberculosis,&quot; <i>J Antimicrob Chemother</i>, 2006, 58(3):701-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/16857689/pubmed\" target=\"_blank\" id=\"16857689\">16857689</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinon M, Scolfaro C, Bignamini E, et al, &quot;Two pediatric Cases of Multidrug-Resistant Tuberculosis Treated With Linezolid and Moxifloxacin,&quot; <i>Pediatrics</i>, 2010, 126(5):e1253-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/20974784/pubmed\" target=\"_blank\" id=\"20974784\">20974784</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schaaf HS, Willemse M, and Donald PR, &quot;Long-Term Linezolid Treatment in a Young Child With Extensively Drug-Resistant Tuberculosis,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(8):748-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/19633523/pubmed\" target=\"_blank\" id=\"19633523\">19633523</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schecter GF, Scott C, True L, et al, &quot;Linezolid in the Teatment of Multidrug-Resistant Tuberculosis,&quot; <i>Clin Infect Dis</i>, 2010, 50(1):49-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/19947856/pubmed\" target=\"_blank\" id=\"19947856\">19947856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaikh ZH, Peloquin CA, and Ericsson CD, &ldquo;Successful Treatment of Vancomycin-Resistant <i>Enterococcus faecium</i> Meningitis With Linezolid: Case Report and Literature Review,&rdquo; <i>Scand J Infect Dis</i>, 2001, 33(5):375-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/11440224/pubmed\" target=\"_blank\" id=\"11440224\">11440224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL, Bisno AL, Chambers HF, et al, &quot;Practice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections,&quot; <i>Clin Infect Dis</i>, 2005, 41(10):1373-406.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/16231249/pubmed\" target=\"_blank\" id=\"16231249\">16231249</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan TQ, &ldquo;Update on the Use of Linezolid: A Pediatric Perspective,&rdquo; <i>Pediatr Infect Dis J</i>, 2004, 23(10):955-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15602197/pubmed\" target=\"_blank\" id=\"15602197\">15602197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Taylor JJ, Wilson JW, and Estes LL, &quot;Linezolid and Serotonergic Drug Interactions: A Retrospective Survey,&quot; <i>Clin Infect Dis</i>, 2006, 43(2):180-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/16779744 /pubmed\" target=\"_blank\" id=\"16779744 \">16779744 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trotman RL, Williamson JC, Shoemaker DM, et al, &quot;Antibiotic Dosing in Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy,&quot; <i>Clin Infect Dis</i>, 2005, 41:1159-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/16163635/pubmed\" target=\"_blank\" id=\"16163635\">16163635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &quot;Practice Guidelines for the Management of Bacterial Meningitis,&quot; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Villani P, Regazzi MB, Marubbi F, et al, &ldquo;Cerebrospinal Fluid Linezolid Concentrations in Postneurosurgical Central Nervous System Infections,&rdquo; <i>Antimicrob Agents Chemother</i>, 2002, 46(3):936-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/11850294/pubmed\" target=\"_blank\" id=\"11850294\">11850294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. <i>Perit Dial Int</i>. 2012;(32 Suppl 2):S32-S86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/linezolid-pediatric-drug-information/abstract-text/22851742/pubmed\" target=\"_blank\" id=\"22851742\">22851742</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12555 Version 192.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F188966\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F188967\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048288\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443849\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048281\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F188942\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F188927\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048291\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F188961\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048290\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F189002\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F188999\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F188947\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F188931\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299606\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F188936\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F188963\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F188938\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F188950\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048287\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F188930\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F188946\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F188949\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F188952\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12555|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">Linezolid: Drug information</a></li><li><a href=\"topic.htm?path=linezolid-patient-drug-information\" class=\"drug drug_patient\">Linezolid: Patient drug information</a></li></ul></div></div>","javascript":null}